Simdax (levosimendan IV) / AbbVie, Orion Corp, Tenax Therap - LARVOL DELTA

CARDIAC SAFETY OF CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPY IN CHILDREN: A SINGLE CENTER EXPERIENCE (EBMT 2026) - "All patients received a lymphodepleting regimen based on cyclophosphamide and fludarabine Mean age was 12±7.3yrs; all patients (62% boys) had normal baseline cardiac function and no signs of pericardial effusion...Signs of overt heart failure, associated with severe reduction in LV ejection fraction at week 2 (mean EF change -23±8%), developed in 4 patients, who needed additional inotropic support (Levosimendan)... Incident cardiac dysfunction in children undergoing CAR T-cell therapy is associated with CRS and type of CAR T cells infused. GLS may be more sensible than EF to screen patients at risk for cardiac events. Our data suggest that in children, mild cardiac dysfunction is frequent after CART-cell therapy, while causing symptomatic heart failure in a minority of patients (3.5%)."

Clinical • Cardiovascular • Congestive Heart Failure • Heart Failure

Ferroptosis in heart failure: from molecular insights to therapeutic implications. (PubMed, Cardiovasc Res) - "It is an abundant form of regulated cell death in the myocardium of many heart failure animal models, including the chronic ischemic, pressure overload, diabetic, septic, obesity-related and doxorubicin-induced cardiomyopathy models...Although definitive causality between ferroptosis and heart failure has not yet been established, emerging evidence suggests that ferroptosis contributes to heart failure progression, supported by multi-layer rescue with classic inhibitors (ferrostatin-1, liproxstatin-1, iron chelators) and by cardiometabolic drugs with clinical efficacy in heart failure (Sodium-Glucose Cotransporter 2 inhibitors, sacubitril/valsartan, finerenone, levosimendan, nicorandil) as well as polyphenols, which restore systolic and/or diastolic indices and reverse remodelling...In this review, through critical synthesis of existing evidence, we analyse current literature, discuss translational barriers and propose a new conceptual mechanistic framework - "the..."

Journal • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Genetic Disorders • Heart Failure • Obesity

Safety and Efficacy of Levosimendan for Acute Ischemic Stroke: A Randomized Controlled Clinical Trial (ChiCTR) - P4 | N=100 | Recruiting | Sponsor: the First Hospital of Jilin University.; the First Hospital of Jilin University. | Not yet recruiting ➔ Recruiting

Enrollment open • Cardiovascular • Ischemic stroke

Study on the Application Value of Levosemindan Combined with Norepinephrine in Acute Myocardial Infarction Complicated by Cardiogenic Shock (ChiCTR) - P=N/A | N=84 | Completed | Sponsor: Fushun People's Hospital, Fushun; Fushun People's Hospital, Fushun

New trial • Cardiovascular • Myocardial Infarction

The Effectiveness of Levosimendan on Veno-Arterial Extracorporeal Membrane Oxygenation Management of Cardiogenic Shock Complicated by Acute Myocardial Infarction: A prospective randomized controlled trial (ChiCTR) - P=N/A | N=1068 | Not yet recruiting | Sponsor: The People’s Hospital of Guangxi Zhuang Autonomous Region; The People’s Hospital of Guangxi Zhuang Autonomous Region

New trial • Cardiovascular • Myocardial Infarction

Response to the letter: Effects of levosimendan on weaning from mechanical ventilation. (PubMed, J Crit Care) - No abstract available

Journal

Effects of Levosimendan in Patients with Severe Mitral Insufficiency and Left Ventricular Dysfunction Undergoing Transcatheter Edge-to-Edge Repair: A Systematic Review and Meta-Analysis. (PubMed, J Cardiovasc Dev Dis) - "Procedural success was higher with Levosimendan, and procedure duration was shorter. These hypothesis-generating findings highlight the need for larger, prospective randomized trials to clarify the role of Levosimendan in this setting."

Journal • Retrospective data • Review • Cardiovascular • Congestive Heart Failure • Heart Failure

Perioperative use of levosimendan in complex congenital heart disease management. (PubMed, Eur J Pediatr) - " In this retrospective cohort of high-risk pediatric patients undergoing complex congenital heart surgery, perioperative levosimendan was not associated with significant differences in in-hospital mortality, postoperative length of stay, or major complications."

Journal • Retrospective data • Cardiovascular • Heart Failure • Pediatrics

Safety of Repeated Levosimendan Use in Chronic Heart Failure. (PubMed, J Cardiovasc Pharmacol) - "Safety and tolerability were acceptable across all groups, with no clinically meaningful changes in hematologic or biochemical markers. The combination of levosimendan and dapagliflozin provides superior clinical benefits in CHF outpatients, including reduced hospitalizations and improved quality of life, while maintaining a favorable safety profile."

Clinical • Journal • Cardiovascular • Congestive Heart Failure • Heart Failure • Hematological Disorders

Levosimendan vs. Milrinone in cardiac surgery: A GRADE-assessed systematic review and meta-analysis. (PubMed, Eur J Clin Pharmacol) - "Levosimendan and Milrinone showed no significant differences in efficacy or safety in cardiac surgery patients. However, wide confidence intervals indicate potential clinically relevant effects. Current evidence does not favor any single agent universally, supporting individualized use based on patient phenotype and institutional practice. Further high-quality trials are needed to confirm."

Clinical • Journal • Retrospective data • Review • Acute Kidney Injury • Cardiovascular • Nephrology • Pediatrics • Renal Disease

Vasoactive Medications and the Microcirculation in Septic Shock: A Scoping Review. (PubMed, Crit Care Med) - "Despite growing interest in perfusion-guided care, significant challenges remain in understanding how vasoactive agents affect the microcirculation. Clarifying these effects through standardized research and point-of-care perfusion monitoring remains a challenge in advancing outcome-driven resuscitation strategies."

Journal • Novel Coronavirus Disease • Septic Shock

Efficacy and Safety of Levosimendan in Severe Cardiac Dysfunction in Children Undergoing Cancer Chemotherapy and Hematopoietic Stem Cell Transplantation. (PubMed, Indian J Hematol Blood Transfus) - "Levosimendan is a safe and effective agent in the treatment of acute heart failure in hemato-oncology patients who maintain normal or high blood pressure. The results have helped tailor supportive critical care in pediatric hemto-oncology patients with cardiac dysfunction."

Journal • Bone Marrow Transplantation • Cardiovascular • Congestive Heart Failure • Critical care • Heart Failure • Hypertension • Oncology • Pediatrics • Transplantation

Effect of levosimendan on plasma intestinal barrier factors in heart failure patients with reduced ejection fraction. (PubMed, Zhong Nan Da Xue Xue Bao Yi Xue Ban) - "Levosimendan not only improves HF and gastrointestinal symptoms in hospitalized patients with acute exacerbation of HFrEF but also reduces plasma intestinal barrier factor levels. These effects may be associated with decreased plasma proinflammatory cytokines and increased anti-inflammatory cytokines after treatment, potentially involving IL-17 and TNF signaling pathways."

Journal • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Gastrointestinal Disorder • Heart Failure • Oncology • Pulmonary Disease • IL10 • IL17A • IL6 • TNFA

Levosimendanin patients with acute myocardial ischaemia undergoing emergency surgical revascularization: RETRACTION. (PubMed, Eur J Anaesthesiol) - No abstract available

Journal • Cardiovascular

Post-acute Myocardial Infarction Complication: A Ventricular Septal Defect. (PubMed, Cureus) - "Hemodynamic support with norepinephrine and levosimendan, along with mechanical ventilation, was crucial for stabilization...This example emphasizes how challenging it can be to manage AMI in elderly people, particularly when unusual side effects like VSD occur. It also highlights how important a multidisciplinary approach is to improving outcomes and optimizing care."

Journal • Acute Coronary Syndrome • Cardiovascular • Congestive Heart Failure • Heart Failure • Myocardial Infarction • Obesity

Letter to the Editor: Effects of levosimendan on weaning from mechanical ventilation: A systematic review and meta-analysis. (PubMed, J Crit Care) - No abstract available

Journal • Retrospective data

LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2 (clinicaltrials.gov) - P3 | N=540 | Recruiting | Sponsor: Tenax Therapeutics, Inc.

New P3 trial • Cardiovascular • Congestive Heart Failure • Heart Failure • Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

Successful Use of Levosimendan in Four Critically Ill Neonates With Pulmonary Hypertension: A Case Series. (PubMed, Pediatr Pulmonol) - No abstract available

Journal • Cardiovascular • Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

Levosimendan in Acute Decompensated Heart Failure (clinicaltrials.gov) - P2/3 | N=332 | Not yet recruiting | Sponsor: Chittagong Medical College

HEOR • New P2/3 trial • Real-world evidence • Cardiovascular • Congestive Heart Failure • Heart Failure

Levosimendan ameliorates cardiomyocyte injury and mitochondrial dysfunction in an Nrf2-dependent manner in mice with sepsis-induced cardiomyopathy. (PubMed, Acta Biochim Biophys Sin (Shanghai)) - "Notably, the protective effects of LEVO on cardiomyocyte viability and mitochondrial function are significantly diminished following Nrf2 inhibition or Nrf2 knockout (KO). Collectively, these findings demonstrate that LEVO mitigates cardiomyocyte injury and mitochondrial dysfunction in SIC through an Nrf2-dependent mechanism."

Journal • Preclinical • Cardiomyopathy • Cardiovascular • Infectious Disease • Inflammation • Metabolic Disorders • Septic Shock • IL6

Hemodynamic effects of levosimendan in low cardiac output syndrome post-CABG refractory to standard inotropic therapy. (PubMed, Med Klin Intensivmed Notfmed) - "This retrospective single-center case series suggests that levosimendan may be associated with hemodynamic improvement in patients with LCOS after CABG who are unresponsive to standard therapy. However, due to the absence of a control group and the retrospective design, these findings should be considered exploratory and hypothesis-generating."

Journal • Cardiovascular • Coronary Artery Disease • Hypotension

Levosimendan to Facilitate Weaning From ECMO in Patients With Severe Cardiogenic Shock: Research Summary. (PubMed, JAMA) - No abstract available

Journal • Cardiovascular

Levosimendan and Weaning From VA-ECMO. (PubMed, JAMA) - No abstract available

Journal

Levosimendan to Facilitate Weaning From ECMO in Patients With Severe Cardiogenic Shock: The LEVOECMO Randomized Clinical Trial. (PubMed, JAMA) - P3 | "Among patients with severe but potentially reversible cardiogenic shock supported by VA-ECMO, early levosimendan administration did not significantly reduce the time to successful weaning of ECMO compared with placebo. ClinicalTrials.gov Identifier: NCT04728932."

Clinical • Journal • Cardiovascular • Critical care • Inflammation • Myocardial Infarction

Prognosis and Risk Stratification of Patients with Advanced Heart Failure Followed-Up on an Outpatient Clinic. (PubMed, Biomedicines) - "Three distinctive patterns of management were recognized and assessed: intermittent levosimendan administration to 33 patients, intermittent intravenous furosemide administration to 17 patients, and 45 patients were followed up exclusively on an outpatient basis with frequent visits... AdvHF patients represent a complex population requiring close follow-up and novel strategies to improve survival. Larger studies are needed to refine and update predictive scores in this population."

Journal • Atrial Fibrillation • Cardiovascular • Chronic Obstructive Pulmonary Disease • Congestive Heart Failure • Coronary Artery Disease • Diabetes • Heart Failure • Immunology • Metabolic Disorders • Pulmonary Disease • Respiratory Diseases